VistaGen and WARF Sign License Agreement for Human Embryonic Stem Cell Technology
News Dec 19, 2008
VistaGen Therapeutics and the Wisconsin Alumni Research Foundation (WARF) have signed a license for human embryonic stem cell patents for the development and commercialization of stem cell-based research tools.
The licensed patents result from the research of stem cell pioneer Dr. James Thompson of the University of Wisconsin Stem Cell & Regenerative Medicine Center and director of regenerative biology at the new Morgridge Institute for Research.
The license will accelerate VistaGen’s commercial programs focused on providing customized, next-generation, stem cell-based predictive toxicology and drug discovery screening assays to increase preclinical R&D productivity for the pharmaceutical industry.
“This agreement with WARF is another critical step in our strategy to become a ‘one-stop-shop’ for the world’s premier stem cell differentiation system,” said Dr. Ralph Snodgrass, VistaGen’s CEO. “It enhances our fundamental expertise for capturing the value of human embryonic stem cell biology for predictive toxicology, drug discovery screening and drug development. When combined with our strong stem cell-based intellectual property estate, the key terms of the new license provide a strong foundation to support our commercial programs focused on high-end R&D services, strategic discovery collaborations and enabling licenses.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE